Pharmacovigilance methods in public health programmes: the example of miltefosine and visceral leishmaniasis

Transactions of the Royal Society of Tropical Medicine and Hygiene

Volumn 105, Issue 2, 2011, Pages 61-67

  Kshirsagar, Nilima ^a   Ferner, Robin ^a   Figueroa, Byron Alfredo Arana ^a   Ghalib, Hashim ^a   Lazdin, Janis ^a  

^a KEM HOSPITAL   (India)

Author keywords

Adverse drug reaction monitoring; Miltefosine; Pharmacovigilance; Public health programmes; Risk minimisation; Visceral leishmaniasis

Indexed keywords

AMPHOTERICIN B; MILTEFOSINE; PENTAMIDINE; STIBOGLUCONATE SODIUM;

BANGLADESH; CLINICAL TRIAL (TOPIC); DIARRHEA; DRUG HALF LIFE; DRUG MEGADOSE; DRUG METABOLISM; DRUG SURVEILLANCE PROGRAM; GASTROINTESTINAL SYMPTOM; HEALTH CARE SYSTEM; HEALTH PROGRAM; HUMAN; INDIA; NEPAL; NEPHROTOXICITY; NONHUMAN; PATIENT SAFETY; REVIEW; RISK FACTOR; SKIN CANCER; VISCERAL LEISHMANIASIS; VOMITING;

ADVERSE DRUG REACTION REPORTING SYSTEMS; ANTIPROTOZOAL AGENTS; CLINICAL TRIALS AS TOPIC; FEMALE; HUMANS; INDIA; LEISHMANIASIS, VISCERAL; MALE; PHARMACOEPIDEMIOLOGY; PHOSPHORYLCHOLINE; PUBLIC HEALTH; RISK FACTORS; VULNERABLE POPULATIONS;

EID: 78651471798     PISSN: 00359203     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.trstmh.2010.11.004     Document Type: Review

References (20)

1. WHO. The importance of pharmacovigilance-safety monitoring of medicinal products. Geneva: World Health Organization; 2002.
2. Haber P., Sejvar J., Mikaeloff Y., DeStefano F. Vaccines and Guillain-Barré Syndrome. Drug Saf 2009, 32:309-323.
3. Sunder S., Chatterjee M. Visceral leishmaniasis-current therapeutic modalities. Indian J Med Res 2006, 123:345-352.
4. Sundar S., Pai K., Sahu M., Kumar V., Murray H.W. Immunochromatographic strip-test detection of anti-K39 antibody in Indian visceral leishmaniasis. Ann Trop Med Parasitol 2002, 96:19-23.
5. Sundar S., Sahu M., Mehta H., Gupta A., Kohli V., Rai M., et al. Noninvasive management of Indian visceral leishmaniasis: clinical application of diagnosis by K39 antigen strip testing at a kala-azar referral unit. Clin Infect Dis 2002, 35:581-586.
6. Sundar S., Jha T.K., Thakur C.P., Enger J., Sindermann H., Fischer C., et al. Oral miltefosine for visceral Leishmaniasis. N Engl J Med 2002, 347:1739-1746.
7. WHO. Regional strategic framework for elimination of kala-azar from the South-East Asia Region (2005-2015). New Delhi, India: World Health Organization Regional Office for South-East Asia; 2005. SEA-VBC-85.(Rev. 1).
8. National Vector Borne Disease Control Programme, Government of India. Guidelines on use of miltefosine. Delhi, India: National Vector Borne Disease Control Programme, Government of India. [accessed 26 October 2010]. http://nvbdcp.gov.in/Doc/Guidelines%20on%20miltefosine.pdf.
9. Sindermann H., Engel J. Development of miltefosine as an oral treatment for leishmaniasis. Trans R Soc Trop Med Hyg 2006, 100(Suppl 1):S17-20.
10. Eypasch E., Lefering R., Kum C.K., Troidl H. Probability of adverse events that have not yet occurred: a statistical reminder. BMJ 1995, 311:619-620.
11. European Medicines Agency. The rules governing medicinal products in the European Union. Vol. 9A. London, UK: European Medicines Agency; 2008.
12. Stoker A., Jeffery R. Pharmaceuticals and health policy: an Indian example. Soc Sci Med 1988, 27:563-567.
13. Joshi A., Narain J.P., Prasittisuk C., Bhatia R., Hashim G., Jorge A., et al. Can visceral leishmaniasis be eliminated from Asia?. J Vector Borne Dis 2008, 45:105-111.
14. Kshirsagar N. The pharmacovigilance system in India. Drug Saf 2005, 28:647-650.
15. WHO. A practical handbook on the pharmacovigilance of antimalarial medicines. Geneva: World Health Organization; 2008.
16. Staedke S.G., Jagannathan P., Yeka A., Bukirwa H., Banek K., Maiteki-Sebuguzi C., et al. Monitoring antimalarial safety and tolerability in clinical trials: a case study from Uganda. Malar J 2008, 7:107.
17. Modayil R.R., Harugeri A., Parthasarathi P., Ramesh M., Prasad R., Naik V., et al. Adverse drug reactions to antiretroviral therapy (ART): an experience of spontaneous reporting and intensive monitoring from ART centre in India. Pharmacoepidemiol Drug Saf 2010, 19:247-255.
18. Mehta U., Durrheim D.N., Blumberg L., Donohue S., Hansford S., Mabuza A., et al. Malaria deaths as sentinel events to monitor healthcare delivery and antimalarial drug safety. Trop Med Int Health 2007, 12:617-628.
19. Gogtay N.J., Mangalvedhekar S.S., Kshirsagar N.A. Adverse drug reaction (ADR) monitoring in India and the postal survey as a useful tool for ADR detection. Pharmacoepidemiol Drug Saf 2000, 9:235-236.
20. European Medicines Agency. ICH Topic E 6 (R1) Guideline for Good Clinical Practice. London: EMEA; July 2002. [accessed 30 October 2010]. http://www.ema.europa.eu/docs/en_GB/document_library/Scientific_guideline/2009/09/WC500002874.pdf.